CA3003085A1 - Cryptophycin compounds and conjugates, their preparation and their therapeutic use - Google Patents
Cryptophycin compounds and conjugates, their preparation and their therapeutic use Download PDFInfo
- Publication number
- CA3003085A1 CA3003085A1 CA3003085A CA3003085A CA3003085A1 CA 3003085 A1 CA3003085 A1 CA 3003085A1 CA 3003085 A CA3003085 A CA 3003085A CA 3003085 A CA3003085 A CA 3003085A CA 3003085 A1 CA3003085 A1 CA 3003085A1
- Authority
- CA
- Canada
- Prior art keywords
- group
- alkyl
- cndot
- formula
- alk
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Plural Heterocyclic Compounds (AREA)
- Bedding Items (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15306751.7 | 2015-11-05 | ||
| EP15306751 | 2015-11-05 | ||
| PCT/EP2016/076603 WO2017076998A1 (en) | 2015-11-05 | 2016-11-03 | Novel cryptophycin compounds and conjugates, their preparation and their therapeutic use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3003085A1 true CA3003085A1 (en) | 2017-05-11 |
Family
ID=54476881
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3003085A Pending CA3003085A1 (en) | 2015-11-05 | 2016-11-03 | Cryptophycin compounds and conjugates, their preparation and their therapeutic use |
Country Status (35)
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI714661B (zh) | 2015-11-05 | 2021-01-01 | 法商賽諾菲公司 | 新穎念珠藻素化合物及接合物、其製備與其治療用途 |
| CN107043380A (zh) | 2016-02-05 | 2017-08-15 | 正大天晴药业集团股份有限公司 | 一种tlr7激动剂的马来酸盐、其晶型c、晶型d、晶型e、制备方法和用途 |
| TN2019000303A1 (en) | 2017-05-10 | 2021-05-07 | Sanofi Sa | Peptidic linkers and cryptophycin conjugates, useful in therapy, and their preparation |
| CN108107103B (zh) * | 2017-12-14 | 2020-10-16 | 华中师范大学 | 谷氨酸受体的质谱探针及其在脑组织中的空间分布规律检测方法 |
| ES2988904T3 (es) | 2019-03-07 | 2024-11-22 | Nobo Medicine Inc | Inhibidores de caspasa y métodos de utilización de los mismos |
| JP2022549971A (ja) | 2019-09-30 | 2022-11-29 | ザ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・ミシガン | クリプトフィシン抗がん剤の生体触媒合成 |
| EP4046996A1 (en) | 2021-02-19 | 2022-08-24 | Universität Bielefeld | Cryptophycin compounds and conjugates thereof |
| CN118742328A (zh) | 2022-02-22 | 2024-10-01 | 阿拉里斯生物技术股份公司 | 包含两个或更多个有效载荷的肽接头 |
| EP4495105A1 (en) | 2023-07-17 | 2025-01-22 | Basf Se | 3-(4-hydroxybut-2-ynoxy)propanoic acid ester, amide and nitrile derivatives as corrosion protection agents |
| EP4495108A1 (en) | 2023-07-17 | 2025-01-22 | Basf Se | 3-[2-(2-oxo-1,3-dioxolan-4-ylidene)ethoxy]propanoic acid derivatives as precursors of monomers in polymerisations |
| WO2025082990A1 (en) | 2023-10-15 | 2025-04-24 | Araris Biotech Ag | Antibody-drug conjugates using two different types of topoisomerase i inhibitors |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0735819B1 (en) * | 1993-12-21 | 2001-07-11 | University Of Hawaii | Cryptophycins |
| US20020128185A1 (en) * | 1998-02-25 | 2002-09-12 | Chuan Shih | Pharmaceutical compounds |
| US7230101B1 (en) | 2002-08-28 | 2007-06-12 | Gpc Biotech, Inc. | Synthesis of methotrexate-containing heterodimeric molecules |
| US20050175619A1 (en) | 2004-02-05 | 2005-08-11 | Robert Duffy | Methods of producing antibody conjugates |
| EP2010475A2 (en) | 2006-04-27 | 2009-01-07 | Intezyne Technologies Incorporated | Heterofunctional poly(ethylene glycol) containing acid-labile amino protecting groups and uses thereof |
| CN101622276B (zh) | 2006-07-18 | 2015-04-22 | 赛诺菲-安万特 | 用于治疗癌症的抗epha2的拮抗抗体 |
| FR2947269B1 (fr) * | 2009-06-29 | 2013-01-18 | Sanofi Aventis | Nouveaux composes anticancereux |
| TW201116297A (en) | 2009-10-02 | 2011-05-16 | Sanofi Aventis | Antibodies that specifically bind to the EphA2 receptor |
| TWI714661B (zh) * | 2015-11-05 | 2021-01-01 | 法商賽諾菲公司 | 新穎念珠藻素化合物及接合物、其製備與其治療用途 |
-
2016
- 2016-11-02 TW TW105135522A patent/TWI714661B/zh active
- 2016-11-03 LT LT16791017T patent/LT3371179T/lt unknown
- 2016-11-03 PT PT167910173T patent/PT3371179T/pt unknown
- 2016-11-03 MA MA43160A patent/MA43160B1/fr unknown
- 2016-11-03 PL PL16791017T patent/PL3371179T3/pl unknown
- 2016-11-03 SI SI201630418T patent/SI3371179T1/sl unknown
- 2016-11-03 ES ES16791017T patent/ES2755101T3/es active Active
- 2016-11-03 TN TNP/2018/000131A patent/TN2018000131A1/en unknown
- 2016-11-03 CN CN201680064372.8A patent/CN108349960B/zh active Active
- 2016-11-03 DK DK16791017T patent/DK3371179T3/da active
- 2016-11-03 CR CR20180256A patent/CR20180256A/es unknown
- 2016-11-03 EP EP16791017.3A patent/EP3371179B1/en active Active
- 2016-11-03 MX MX2018005379A patent/MX374535B/es active IP Right Grant
- 2016-11-03 CA CA3003085A patent/CA3003085A1/en active Pending
- 2016-11-03 HR HRP20191729 patent/HRP20191729T1/hr unknown
- 2016-11-03 SG SG11201803181SA patent/SG11201803181SA/en unknown
- 2016-11-03 EA EA201890898A patent/EA035625B1/ru not_active IP Right Cessation
- 2016-11-03 US US15/768,792 patent/US10941139B2/en active Active
- 2016-11-03 MY MYPI2018701424A patent/MY189448A/en unknown
- 2016-11-03 KR KR1020187015447A patent/KR102822076B1/ko active Active
- 2016-11-03 HK HK18115834.8A patent/HK1256754B/en unknown
- 2016-11-03 RS RS20191429A patent/RS59498B1/sr unknown
- 2016-11-03 JP JP2018541548A patent/JP6929292B2/ja active Active
- 2016-11-03 AU AU2016347724A patent/AU2016347724B2/en active Active
- 2016-11-03 HU HUE16791017A patent/HUE046033T2/hu unknown
- 2016-11-03 WO PCT/EP2016/076603 patent/WO2017076998A1/en not_active Ceased
- 2016-11-04 UY UY0001036979A patent/UY36979A/es not_active Application Discontinuation
- 2016-11-04 AR ARP160103379A patent/AR106604A1/es not_active Application Discontinuation
-
2018
- 2018-04-10 ZA ZA2018/02322A patent/ZA201802322B/en unknown
- 2018-04-20 PH PH12018500852A patent/PH12018500852B1/en unknown
- 2018-04-27 CO CONC2018/0004581A patent/CO2018004581A2/es unknown
- 2018-05-01 IL IL259067A patent/IL259067B/en unknown
- 2018-05-03 EC ECIEPI201834035A patent/ECSP18034035A/es unknown
- 2018-05-04 CL CL2018001210A patent/CL2018001210A1/es unknown
-
2019
- 2019-11-06 CY CY20191101166T patent/CY1122441T1/el unknown
-
2020
- 2020-12-10 US US17/118,204 patent/US20210163458A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA3003085A1 (en) | Cryptophycin compounds and conjugates, their preparation and their therapeutic use | |
| CA2937731C (en) | Bifunctional cytotoxic agents | |
| EP2780039B9 (en) | Cytotoxic peptides and antibody drug conjugates thereof | |
| AU2018265333B2 (en) | Peptidic linkers and cryptophycin conjugates, useful in therapy, and their preparation | |
| HK1256754A1 (en) | Novel cryptophycin compounds and conjugates, their preparation and their therapeutic use | |
| JP6957629B2 (ja) | 非線状自壊性リンカーおよびそのコンジュゲート | |
| CA3202759A1 (en) | Mcl-1 inhibitor antibody-drug conjugates and methods of use | |
| BR112018008490B1 (pt) | Compostos e conjugados de criptoficina, processos para a preparação dos mesmos, medicamento e composição farmacêutica | |
| KR20240016231A (ko) | 신규 오리스타틴 전구약물 | |
| NZ741734B2 (en) | Novel cryptophycin compounds and conjugates, their preparation and their therapeutic use | |
| EA045708B1 (ru) | Новые пептидные линкеры и конъюгаты на основе криптофицина, их получение и их терапевтическое применение | |
| HK1233252A1 (en) | Bifunctional cytotoxic agents | |
| HK1233252B (zh) | 双功能细胞毒类药剂 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20211021 |
|
| EEER | Examination request |
Effective date: 20211021 |
|
| EEER | Examination request |
Effective date: 20211021 |
|
| EEER | Examination request |
Effective date: 20211021 |
|
| EEER | Examination request |
Effective date: 20211021 |
|
| EEER | Examination request |
Effective date: 20211021 |
|
| EEER | Examination request |
Effective date: 20211021 |
|
| EEER | Examination request |
Effective date: 20211021 |